After a past deal with Evolus to sell the product in the U.S. and Europe, Daewoong is searching for other markets in Asia and Latin America for its Botox competitor, and has just linked up with Turkey's Seltek.
SEOUL – South Korea’s Daewoong Pharmaceutical Co. Ltd. has signed a licensing deal with Seltek for the approval and commercialization in Turkey of Nabota (botulinum toxin), a drug administered via injection to improve the frown lines by weakening or paralyzing certain muscles or nerves.
Noting that the current market for botulinum toxin in Turkey is rising more than 24% each year, Daewoong, a major...
50% tariffs on US imports from India, a range on others, an uncertain outcome of Section 232 investigations of pharma and talk of BRICS tariffs are making forecasting for the pharma industry extremely difficult, Scrip finds in this infographic analysis
Sumitomo Pharma's iPSC therapy for Parkinson's has been filed for approval in Japan after showing safety and efficacy in a Phase I/II trial and may become one of the first such therapies to reach the market in the country, which has invested heavily in the modality.
Yuhan and GC Biopharma’s performances stood out among South Korean companies reporting Q2 results, boosted by license income, strong global growth and exports, while many others reported generally weaker figures.
